BPC-157 for gut healing: IBD, GERD, ulcers
BPC-157's most clinically-defensible use case is gut healing. The protocol for IBD, GERD, ulcers, and leaky gut, plus what the human evidence actually shows.
Updated May 7, 2026 · 5 min read
BPC-157's most clinically-defensible use case isn't tendon repair — it's gut healing. The peptide was originally isolated from gastric juice as part of a larger gastric protective protein, and the strongest pre-clinical signals are in the GI tract: ulcer protection, IBD reduction, esophageal healing, and gut-barrier restoration.
This cluster covers the protocol patterns, what the human evidence actually shows, and where to be appropriately cautious.
The conditions BPC-157 is most reported for
| Condition | Reported response | Confidence |
|---|---|---|
| Gastric ulcers (NSAID-induced, stress-induced) | Strong protection in animal models | Pre-clinical strong, human limited |
| GERD / reflux | Reduced symptoms in user reports | Pre-clinical moderate, anecdotal |
| IBD (Crohn's, ulcerative colitis) | Reduced flare severity, mucosal healing | Pre-clinical strong, small human case series |
| Leaky gut / intestinal permeability | Improved barrier function | Pre-clinical promising, no human RCTs |
| H. pylori adjunct | Mixed reports | Limited |
| Post-antibiotic gut recovery | Faster microbiome rebuild reported | Anecdotal only |
| Esophagitis | Mucosal healing in animal models | Pre-clinical moderate |
The gut indications have the most coherent mechanistic story behind them. BPC-157 protects the gastric mucosa, modulates the inflammatory response in the gut, and supports tight-junction integrity. These are the same mechanisms targeted by standard GI drugs, just from a different angle.
The mechanism in the gut
In gut tissue, BPC-157 acts through several pathways simultaneously:
- Mucosal protection — increasing the protective mucus layer over the gastric and intestinal lining
- Tight-junction support — strengthening the connections between intestinal epithelial cells (the leaky-gut mechanism)
- Inflammatory modulation — reducing pro-inflammatory cytokine signaling in the gut
- Microcirculation — improving blood flow to damaged mucosa, which speeds healing
- Nitric oxide pathway interaction — interacts with the same signaling that protects against NSAID damage
This multi-pathway action is why animal studies show benefit across so many GI insult models — NSAID-induced ulcers, stress ulcers, alcohol-induced damage, chemically-induced colitis. The peptide doesn't fix one specific lesion; it shifts the gut's overall protective and repair signaling.
The protocol most reported for gut goals
| Goal | Dose | Route | Duration |
|---|---|---|---|
| Mild GERD / minor reflux | 250 mcg/day | Oral, morning empty stomach | 4 weeks |
| IBD flare adjunct | 500 mcg/day | Oral, twice daily, empty stomach | 6–8 weeks |
| Active ulcer (post-diagnosis, with clinician) | 500 mcg/day | Oral, twice daily, empty stomach | 6–8 weeks |
| Post-antibiotic recovery | 250 mcg/day | Oral, morning | 4 weeks |
| General gut maintenance | 250 mcg/day | Oral, morning | 4 weeks, 1–2x/year |
For gut goals, oral is the route. Injection adds nothing — the target tissue is the gut itself, and oral delivery puts the peptide there directly.
How to take it
The standard oral protocol:
- Reconstitute the vial (5 mg + 2 mL BAC water = 2.5 mg/mL is typical)
- Draw the dose into an oral syringe — for 250 mcg, that's 0.1 mL (10 units on an insulin syringe with the needle removed)
- Take on an empty stomach — first thing in the morning is ideal
- Hold under the tongue for 30–60 seconds before swallowing
- Wait 30 minutes before eating, drinking coffee, or taking other medications
For twice-daily dosing, the second dose is typically before bed (also empty stomach, at least 2 hours after the last meal).
What the human evidence shows
Honest read of the clinical literature:
- Multiple case series in inflammatory bowel disease show symptomatic improvement and mucosal healing on endoscopy
- No large RCTs in any GI condition — the trial infrastructure that exists for mesalamine, infliximab, etc. doesn't exist for BPC-157
- Strong pre-clinical record across virtually every animal GI injury model tested
- Theoretical advantages over standard GI drugs — non-suppressive (doesn't shut down acid like PPIs), no immunosuppression (unlike biologics), oral-active
The honest position: this is the most-evidence-supported use of BPC-157, and it's still evidence that wouldn't pass FDA's bar for an indication. That's not the same as "it doesn't work" — it's "the regulatory case hasn't been built."
Where to be cautious
The gut indications are the safest application of BPC-157, but a few specific cautions apply:
- Active GI bleeding — get medical evaluation before adding any peptide. BPC-157's pro-angiogenic effects could in principle complicate bleeding management.
- Active GI cancer or precancerous polyps — absolute caution. The cancer-related caveats apply.
- Diverticulitis flares — the inflammatory mechanism is different from IBD; case reports are mixed
- Active H. pylori infection — treat the infection first; BPC-157 isn't antibacterial
- Pregnancy — not studied. Don't.
- Concurrent biologics for IBD — talk to your gastroenterologist before adding anything
Practical sequencing if you're considering it
Reasonable order of operations:
- Get a real diagnosis first. "I think it's leaky gut" is not the same as a confirmed diagnosis. Imaging, scoping, and labs matter.
- Try first-line treatments first. PPIs for GERD, mesalamine for UC, dietary trials for IBS.
- If first-line is inadequate, BPC-157 is a reasonable adjunct — discuss with your clinician before starting
- Run a defined trial — 4–8 weeks at the protocol above, with documented baseline symptoms
- Continue if it helps; stop if it doesn't. Don't drift into chronic indefinite use without a goal
Combining with standard GI care
BPC-157 doesn't conflict with most standard GI medications:
- PPIs (omeprazole, esomeprazole) — fine to combine
- H2 blockers — fine
- Mesalamine / sulfasalazine — fine
- Probiotics — fine, often complementary
- Antibiotics — fine, BPC-157 isn't antimicrobial
Where there's possible interaction: NSAIDs (BPC-157 protects against NSAID damage, so combining is sometimes reported as protective; long-term high-dose NSAID with BPC-157 is not well-studied) and biologics (talk to your prescriber).